• Radiation Oncology Journal
• /
• 제1권1호
• /
• pp.61-67
• /
• 1983

Two cases of primary malignant lymphoma of the brain and six cases of secondary CNS lymphoma seen at Yonsei cancer center, radiotherapy department for recent 4 years are presented. Primary lymphomas revealed single tumor mass on corpus callosum area and secondary lymphoma were intracranial (3 cases) or leptomeningeal type (3 cases). Histology of primary lymphoma were reticulum cell sarcoma and secondary lymphomas were either diffuse histiocytic or diffuse poorly differentiated lymphocytic lymphoma. All patients showed good response to radiation. Two patients with primary CNS lymphoma and two of six secondary CNS lymphoma are alive after radiotherapy (34, 31, 26, 12 months). But the prognosis of secondary CNS lymphoma is grave, because of progressive systemic disease. Incidence, risk factors, diagnosis and therapeutic management of CNS involvement are also discussed.

• Journal of Korean Neurosurgical Society
• /
• 제42권3호
• /
• pp.220-223
• /
• 2007

We report a case of dural marginal zone lymphoma which showed the usual radiological findings resembling meningioma. A 59-year-old woman presented with headache. Initial computed tomography and magnetic resonance images showed a frontal convexity meningioma. The patient underwent a craniotomy and subtotal (simpson grade II) resection of tumor was done. Pathological examination confirmed an extranodal marginal zone B-cell lymphoma of Mucosa-Associated Lymphoid Tissue (MALT). The lesion was composed of a lymphoid mass with irregularly shaped follicles surrounded by many monomorphic small lymphocytes and a stained marginal zone for B-cell markers CD20 and CD29a. The natural history of primary CNS lymphoma and MALT type lymphoma are different. B-cell MALT lymphoma can mimic meningioma in its radiological features. Accordingly, MALT lymphoma of the CNS must be considered in the differential diagnosis of meningioma.

• Journal of Korean Neurosurgical Society
• /
• 제37권4호
• /
• pp.296-299
• /
• 2005

We report a case of primary central nervous system(CNS) lymphoma in an organ recipient. A 33-years-old man who underwent a renal transplantation 3years previously presented with headache and vomiting. In Brain computed tomography scans and magnetic resonance images showed multiple periventricular cystic rim enhancing masses. Pathologic diagnosis by stereotactic biopsy revealed malignant non-Hodgkins B-cell lymphoma. After pathologic confirmation, methotrexate chemotherapy and whole brain radiation therapy were done. Having experienced such a case, the authors strongly recommend to add primary CNS lymphoma as one of the differential diagnoses to brain abscess, metastatic brain tumor and glioblastoma multiforme in cases of multiple ring enhancing periventricular lesions of immunocompromised patient or organ recipient.

• Journal of Korean Neurosurgical Society
• /
• 제29권12호
• /
• pp.1628-1633
• /
• 2000

Objective : The incidence of primary CNS lymphoma(PCNSL) has been increasing recently. The purpose of this study is to establish of prognostic factors and treatment options for PCNSL. Methods : Thirty-one PCNSL patients were treated in our institute between 1985 and 1997. All patients were histologically confirmed via stereotactic biopsy or open biopsy. The authors retrospectively analyzed clinical characteristics of PCNSL and prognostic factors, including histological cell types, immunohistological cell types and treatment options of PCNSL. Our data were statistically analyzed using Kaplan Meier survival curve and multivariated ANOVA test. Results : The clinical and radiological characteristics of PCNSL were resembled to those of other reports. The most common histological subtype was diffuse large cell type(55.5%). In immunohistolgical study, the incidence of T-cell lymphoma(35.7%) was very higher than that of others. The radiotherapy could prolonged patients' survival(p=0.021). One-year and 3-year survival rate of PCNSL were 66.9% and 45.9%, respectively. One-year survival rate of B cell and T cell lymphoma were 72.7% and 50.0%, respectively. The patients with B-cell lymphoma showed better prognosis than patients with T-cell lymphoma(p=0.049). Conclusion : On the basis of our data, active radiotherapy could prolong patients' survival. the T-cell lymphoma revealed higher incidence than those of other reports and had poor prognosis than that of B cell lymphoma.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권11호
• /
• pp.4733-4738
• /
• 2014

Purpose: We developed and evaluated a regimen including fotemustine, teniposide and dexamethasone (FTD) for treating patients with central nervous system (CNS) lymphoma based on pharmacokinetic properties of individual agents and in combination. Patients and Methods: In a comparison study, 8 patients with primary CNS lymphoma (PCNSL) and 8 with secondary CNS lymphoma (SCNSL) were treated with FTD (comprising fotemustine 100 mg/m2, 1h infusion, day 1; teniposide 60 mg/m2, >0.5 h infusion, on day 2, 3, 4; dexamethasone 40 mg, 1h infusion, on day 1, 2, 3, 4 and 5; and methotrexate 12 mg, cytosine arabinoside 50 mg plus dexamethasone 5 mg intrathecally, on day 2 and 7). Cycles were repeated every 3 weeks. After response assessment, patients received whole brain radiotherapy. Results: Of the 8 PCNSL patients, 4 (50%) achieved CR and 3 (38%) PR, an overall response rate of 88%. Four patients (50%) were in continuing remission at the end of this study after a median follow-up of 30 months (range 10 to 56 months). Of the 8 SCNSL patients the overall response rate was 63% (CR+PR: 38%+25%). All responses were achievable with predictable toxicity mainly reflecting reversible myelosuppression. Conclusion: This study suggests that FTD could be an effective treatment for CNS lymphoma, and is worthy of further evaluation.

• Journal of Korean Neurosurgical Society
• /
• 제50권4호
• /
• pp.304-310
• /
• 2011

Objective : Intrathecal methotrexate (MTX) therapy combined with whole brain radiotherapy (WBRT) is one of the major treatment modalities for leukemia and lymphoma involving the central nervous system (CNS). The purpose of this study was to retrospectively determine the incidences of leukoencephalopathy and disseminated necrotizing leukoencephalopathy (DNL) following intrathecal MTX therapy for CNS lymphoma or leukemia and to assess the potential risk factors. Methods : Between January 2000 and August 2009, 143 patients with CNS lymphoma or leukemia received intrathecal MTX therapy alone or in combination with WBRT at a single institution. Patients were followed up clinically and radiologically at regular two- or three-month intervals. Medical records were reviewed to obtain information regarding the patients' demographics, medical histories, radiologic characteristics, treatments, and clinical courses. Results : On follow-up MR images, leukoencephalopathy was found in 95 of 143 patients (66.4%). The median time to develop leukoencephalopathy was 6.6 months. Among those with leukoencephalopathy, four patients showed seven extensive white-matter changes with strongly enhancing lesions demonstrating DNL. Histological confirmation was done in six lesions of three patients and radiological diagnosis alone in one patient. Four lesions spontaneously disappeared on MR images without any treatment, with a mean duration of 14 months before disappearance of DNL. Conclusion : Leukoencephalopathy is a common phenomenon that occurs following intrathecal MTX therapy; however, DNL occurs at a very low incidence. For newly developed enhancing lesions, consideration for the occurrence of DNL should be taken to avoid unnecessary invasive procedures or therapies.

• 대한자기공명의과학회:학술대회논문집
• /
• 대한자기공명의과학회 1999년도 제4차 추계학술대회 초록집
• /
• pp.41-41
• /
• 1999

• Investigative Magnetic Resonance Imaging
• /
• 제8권2호
• /
• pp.86-93
• /
• 2004

목적 : 수소 자기공명분광법이 미만성 침습성 양상의 일차성 중추신경 림프종의 감별진단에 도움을 주는가에 대하여 알아보고자 하였다. 대상 및 방법 : 정위적 생검에 의해 확진된 7명의 일차성 중추신경 림프종 환자의 수술 전 임상양상 및 자기공명영상을 알아보았으며, 수소 자기공명분광법의 소견을 후향적으로 조사하였다. 정량 분석을 위하여, 자기공명분광법의 스펙트럼에서 Choline(Cho), N-acetyl aspartate (NAA), 그리고 lipid-lactate(Lip-Lac)의 creatine (Cr)에 대한 상대적인 값을 구하였다. 결과 : Cho/Cr의 평균은 $1.80{\pm}0.95$, NAA/Cr의 평균은 $1.34{\pm}0.41$, Lip-Lac/Cr은 $1.12{\pm}0.16$였다. 전례에서 Lip-Lac/Cr의 통계학적으로 유의한 증가 소견을 보였다. 7예 중 2예의 종괴를 형성하는 경우 NAA/Cr 의 유의한 감소를 보였지만 종괴형성이 분명하지 않은 경우 NAA/Cr의 감소는 없었다. 결론 : 수소자기공명분광법에서 Lip-Lac 피크 출현에도 불구하고 NAA 피크의 현저한 감소가 동반되지 않는 소견은 종괴를 형성하지 않는 미만성 침습성 림프종을 진단하는데 도움을 주는 소견으로 생각된다.

• Journal of Korean Neurosurgical Society
• /
• 제40권1호
• /
• pp.54-57
• /
• 2006

Central nervous system[CNS] involvement of acute lymphoblastic leukemia may occur. However, CNS involvement as a first manifestation of leukemia is very rare. An 8-year-old girl complained of a backache after playing in the water. Neurological examination detected progressing paraparesis. Magnetic resonance imaging[MRI] of the thoracolumbar spine showed a well-circumscribed homogeneous posterior extradural mass lesion extending from T7 to T9. MRI of the brain showed diffused fatty marrow replacement of the calvarium and the skull base. We report a patient with epidural Burkitt's lymphoma of the thoracic and lumbar vertebra causing compression of the spinal cord after pathologic evaluation. The tumor consisted mainly of lymphoblastic cells, which were identical to those originally seen in the bone marrow aspiration and biopsy. After decompressive laminectomy she began consolidation chemotherapy.

• Radiation Oncology Journal
• /
• 제12권1호
• /
• pp.33-42
• /
• 1994

1982년부터 1991년까지 경희대학병원 치료방사선과에서 원발성 중추신경계 림프종으로 확진되어 방사선치료를 받은 16명의 환자를 대상으로 치료결과를 후향적으로 분석하였다. 가장 흔한 세포아형은 large, noncleaved cell과 B cell의 immunoblastic 림프종이었으며 측두엽과 심핵부위에 호발하였다. 치료는 환자를 생검 또는 절제술후 전뇌에 40 Gy(range=30-50 Gy)를 방사선 조사하였으며 원발병소에 15-20 Gy를 추가조사하였다. 16명의 환자중 14명은 방사선치료후 2개월에서 49개월 사이에 사망하였으며, 2명은 재발없이 각각 8개월과 22개월째 생존하고 있다. 1년 및 2년생존율은 각각 55.6$ \% $와 34.7$ \% $이었고, 중간 생존기간은 12개월이었다. 16명의 환자중 재발된 11명을 분석하였다. 방사선치료후 원발부위에 재발은 드물었으나 전뇌조사에서 불구하고 다른 부위에서 재발하였다. 재발율은 뇌에서 68.7$ \% $ (l1/16)이고 척추에서 25.0$ \% $(4/16)이었다. 나이, 성별 발생부위, 병소수, 방사선치료선량등은 각각 생존율과 무관하였다. 이와 같은 결과로 중추신경계 림프종은 방사선 치료의 초기반응은 양호하나 통상적인 방사선치료만으로는 조절이 어려운 질환이다. 따라서 분할치료방법에 의한 방사선량 증가와 항암제의 병용으로 중추신경계 림프종에 대한 치료효과를 향상시키리라 기대한다.